PDCD1 and neoplasm: Our ABM predicts ex vivo immune activation with > 80% accuracy, whereas meta‐analyses examining established clinical biomarkers for anti‐PD‐1/PD‐L1 therapy, including PD‐L1 expression on tumor cells, tumor‐mutational burden (TMB), and tumor-infiltrating lymphocytes (TIL), report pooled AUCs of roughly 0.6–0.7 across tumor types [27].